Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTGBPJE)

• DTT Name: PI3-kinase delta (PIK3CD) DTT Info
• Gene Name: PIK3CD

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[1]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[2]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[3]
Leniolisib	DMWAD93	Stomach cancer	2B72	Approved	[4]
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[5]

15 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[6]
AZD8154	DMK13L1	Asthma	CA23	Phase 2	[7]
INCB50465	DMZJP2T	Diffuse large B-cell lymphoma	2A81	Phase 2	[8]
ME-401	DMK0UOY	Follicular lymphoma	2A80	Phase 2	[8]
Parsaclisib	DMYBIFS	Follicular lymphoma	2A80	Phase 2	[9]
RP6530	DMYILGK	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[8]
INCB40093	DMED9QV	Lymphoma	2A80-2A86	Phase 1/2	[10]
PA-799	DMLSYJQ	Colorectal cancer	2B91.Z	Phase 1/2	[11]
ZX-101A	DM65AV2	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[12]
AMG 319	DM9P0NA	Hematologic tumour	2B33.Y	Phase 1	[13]
BGB-10188	DM84LXE	B-cell lymphoma	2A86	Phase 1	[14]
GS-9820	DMNX3US	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[15]
GS-9901	DMGHN98	Haematological malignancy	2B33.Y	Phase 1	[16]
GSK2292767	DMIX891	Asthma	CA23	Phase 1	[17]
HMPL-689	DMEGN5I	Lymphoma	2A80-2A86	Phase 1	[18]

1 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrrolo[2,3-d]pyrimidine derivative 28	DMXRJI2	N. A.	N. A.	Patented	[19]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XL-499	DMINSA5	Solid tumour/cancer	2A00-2F9Z	Preclinical	[20]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Wortmannin	DM8EVK5	Haematological malignancy	2B33.Y	Terminated	[21]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DM3FH02	Discovery agent	N.A.	Investigative	[22]
ETP-46321	DMO2PY8	Rheumatoid arthritis	FA20	Investigative	[23]
IC87114	DMM50ED	Discovery agent	N.A.	Investigative	[21]
IC980033	DM8L6WB	Discovery agent	N.A.	Investigative	[21]
LY-292223	DML36ZE	Discovery agent	N.A.	Investigative	[22]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [4] Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [7] Discovery of AZD8154, a Dual PI3Kgamma-delta Inhibitor for the Treatment of Asthma. J Med Chem. 2021 Jun 24;64(12):8053-8075.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.
• [10] INCB40093 is a selective PI3Kdelta inhibitor with potent antiproliferative activity against human B-cell tumors.
• [11] The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
• [12] Clinical pipeline report, company report or official report of Zenshine Pharmaceuticals
• [13] National Cancer Institute Drug Dictionary (drug id 696292).
• [14] ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health.
• [15] National Cancer Institute Drug Dictionary (drug id 741949).
• [16] Clinical pipeline report, company report or official report of Gilead.
• [17] Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase delta Inhibitor. J Pharmacol Exp Ther. 2019 Jun;369(3):443-453.
• [18] Clinical pipeline report, company report or official report of Hutchison MediPharma.
• [19] Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
• [20] Clinical pipeline report, company report or official report of Exelixis.
• [21] Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9.
• [22] LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.
• [23] ETP-46321, a dual p110alpha/ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol. 2016 Apr 15;106:56-69.